LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Immunoassay Analyzer Introduced at 2016 AACC Annual Meeting

By LabMedica International staff writers
Posted on 12 Aug 2016
Print article
Image: The Atellica Solution, a highly flexible immunoassay and clinical chemistry analyzer (Photo courtesy of Siemens Healthineers).
Image: The Atellica Solution, a highly flexible immunoassay and clinical chemistry analyzer (Photo courtesy of Siemens Healthineers).
The recently renamed medical instrument manufacturer Siemens Healthineers (Erlangen, Germany) chose the July 31 - August 4, 2016, AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA) as the venue for introducing its new Atellica Solution automated immunoassay and clinical chemical analyzer system.

In May 2016, Siemens Healthcare changed its name to Healthineers, a name that embodied the company’s pioneering spirit and engineering expertise in the healthcare industry. It is unique and bold name and gives a new identity to the organization and to its employees who serve and inspire healthcare providers worldwide.

One of Healthineers' dynamic new products is the Atellica Solution. This highly flexible immunoassay and clinical chemistry solution features patented bi-directional magnetic sample-transport technology that allows the system to operate 10 faster than conventional conveyors. The platform boasts a multi-camera vision system and intelligent sample routing that allows independent control over every sample from routine assays to STATs.

Atellica Solution, which can handle more than 30 sample container types including pediatric and special containers, can be used as a stand- alone instrument, or it can be scaled up to 10 components with more than 300 customizable configurations. The system supports remote-access monitoring and control, which maximizes instrument uptime, with a broad and expanding assay menu using proven detection technologies.

"We engineered the Atellica Solution based on our customers' needs and extensive research of market trends," said Franz Walt, president of laboratory diagnostics at Siemens Healthineers. "The result is a game-changer that delivers control and simplicity, so our customers can focus on driving better business and clinical outcomes and spend less time managing operations."

The Atellica Solution is currently being evaluated by the Food and Drug Administration and is not yet available in the United States.

Related Links:
Siemens Healthineers
AACC Annual Meeting & Clinical Lab Expo
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more